{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Consolidating Benefit with Newer Options for ADHD: Core Symptom Control in Large Trials - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"QGc0rR509J\"><a href=\"https:\/\/themedicalxchange.com\/en\/2014\/06\/09\/3rd-eunethydis-international-conference-on-adhd\/\">Consolidating Benefit with Newer Options for ADHD: Core Symptom Control in Large Trials<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2014\/06\/09\/3rd-eunethydis-international-conference-on-adhd\/embed\/#?secret=QGc0rR509J\" width=\"600\" height=\"338\" title=\"&#8220;Consolidating Benefit with Newer Options for ADHD: Core Symptom Control in Large Trials&#8221; &#8212; The Medical Xchange\" data-secret=\"QGc0rR509J\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/06\/2337_Eunethydis_2014_EN_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Istanbul \u2013 The efficacy of alternative therapies for the control of attention deficit hyperactivity disorder (ADHD) has been validated in a series of studies presented at the 3rd EUNETHYDIS Conference. Stimulant medications are the guideline-recommended first-line therapy for ADHD, but up to 30% of ADHD patients do not respond adequately to these agents, according to published studies and new data presented here. The alternatives for stimulants include a selective alpha-2a (\u03b12a) receptor agonist and a selective norepinephrine reuptake inhibitor (SNRI). Each was associated with highly-significant reductions in the core ADHD symptoms of hyperactivity, inattention, and impulsivity in a series of large multicenter, placebo-controlled trials. The objective evidence included data specifically collected with the selective \u03b12a receptor agonist in adolescents, a group that has not been uniformly included in previous ADHD studies with this agent. These new data outline an evidence-based strategy for improving ADHD control in those with symptoms despite optimized first-line therapy."}